AI 资本情报
Discovery Ventures · 机构档案
机构速览
Discovery Ventures 是一家专注医疗健康、生物技术的风险投资团队。官网自述其关注人工智能、基因治疗、纳米技术和仿生学等领域。
来源核验日期： · 本档案包含官网、本人公开资料或一手披露核验内容；详细来源和原文摘录见下方。
本库收录的融资关联
- BigHat Biosciences2026-09-24 · C轮 · 7500 万美元
关联仅表示收录记录中的参与，不代表完整投资组合或投资收益。
基本信息
| 官网披露投资方向 | 医疗健康与生物技术，官网列出人工智能、基因治疗、纳米技术和仿生学等方向。 来源 3 |
|---|---|
| 官网自述发展历程 | 官网称团队在医疗健康投资领域有超过 15 年的历史；这是机构自述，不代表法定成立日期。 来源 2 |
公开成绩与记录
- BigHat Biosciences 2026 年 9 月 24 日的 Series C 公告将 Discovery Ventures 列为该公司的既有投资方。 来源 1
- 融资来源记录：BigHat Biosciences · C轮 · 2026-09-24 · 本轮参投 · $75 million。这是本库收录的披露案例，不代表完整投资组合。 来源 4
官方联系方式
- 机构官网：Discovery Ventures
原始来源
- 1. BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
SAN MATEO, CALIFORNIA - September 24, 2026: BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced the completion of a $75 million Series C financing, bringing its total funding raised to date to $223 million. The round was co-led by DFJ Growth & Premji Invest with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group, and existing investors including 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz (a16z), Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Quadrille Capital, and Section 32. About BigHat Biosciences: BigHat Biosciences is an AI-native biotechnology company designing and developing next-generation protein
- 2. Discovery Ventures
We are a leading healthcare VC firm, building on a 15+ year history with a proven track record of success Submit Pitch Partnering with the Next Generation of Biotech & Healthcare Leaders Global Scale. Founder-focused. Discovery Ventures™ combines deep technical expertise, smart capital and a global network to accelerate biomedical innovation. Discovery Ventures unleashes the potential of groundbreaking biotech with
- 3. Discovery Ventures
From Artificial Intelligence and Gene Therapy to Nanotechnology and Bionics, we provide the capital and strategic guidance needed to scale next-generation technology. Our Track Record is Your Advantage. For over 15 years, our team has served as a trusted partner to the biotech ecosystem. Our team combines deep technical expertise with a proven track record, having played key roles in some of the industry’s most
- 4. BigHat Biosciences 宣布完成 7500 万美元 C 轮融资，以推进 AI 设计的治疗药物和领先的智能体数据平台，用于快速蛋白质设计
existing investors including 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz (a16z), Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Quadrille Capital, and Section 32.